February 25, 2022 11:16 AM ESTUpdated 03:36 PM
R&D

Russ­ian in­va­sion of Ukraine threat­ens hun­dreds of clin­i­cal tri­als

Paul Schloesser

Associate Editor

Day 2 of the Russ­ian in­va­sion has brought head­lines of a bat­tle for the na­tion’s cap­i­tal, signs that mil­lions of Ukraini­ans may be­come refugees and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times